Thursday, 15 October 2026European Markets

HOME INVEST BE., CRCAM SUD R.A.CCI, Another 2 Companies Have A High Estimated Dividend Yield

Loading stream...

(vianews) - home invest be. (homi.br), crcam sud r.a.cci (crsu.pa), barbara bui (bui.pa) have the highest dividend yield stocks on this list.

financial asset forward dividend yield updated (est)
home invest be. (homi.br) 6.75% 2024-03-08 08:20:08
crcam sud r.a.cci (crsu.pa) 5.39% 2024-03-08 09:01:54
barbara bui (bui.pa) 4.08% 2024-03-04 09:00:14
tipiak (tipi.pa) 2.48% 2024-03-04 09:23:51

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. home invest be. (homi.br)

6.75% foward dividend yield

home invest be.'s last close was €15.06, 29.13% below its 52-week high of €21.25. intraday change was 1.86%.

home invest belgium s.a. operates as a real estate investment company in belgium. it primarily invests in residential properties. as of december 31, 2008, the company's real estate portfolio consisted of 992 rental units with a total rentable space of approximately 111,091 square meters. the company was formerly known as home invest and changed its name to home invest belgium s.a. in may 1999. home invest belgium s.a. was founded in 1980 and is based in brussels, belgium.

earnings per share

as for profitability, home invest be. has a trailing twelve months eps of €-0.23.

revenue growth

year-on-year quarterly revenue growth declined by 1.3%, now sitting on 36.96m for the twelve trailing months.

more news about home invest be..

2. crcam sud r.a.cci (crsu.pa)

5.39% foward dividend yield

crcam sud r.a.cci's last close was €115.50, 16.18% below its 52-week high of €137.80. intraday change was -0.43%.

caisse régionale de crédit agricole mutuel sud rhône alpes provides various banking products and services in france. the company offers accounts and cards; savings; credits, including real estate loans, consumer and vehicle loans, and work credits; and insurance products, such as home, car and two wheels, health and wheeler, leisure and daily, and borrower insurance. caisse régionale de crédit agricole mutuel sud rhône alpes was incorporated in 1995 and is based in grenoble, france. caisse régionale de crédit agricole mutuel sud rhône alpes is a subsidiary of parts sociales.

earnings per share

as for profitability, crcam sud r.a.cci has a trailing twelve months eps of €22.95.

pe ratio

crcam sud r.a.cci has a trailing twelve months price to earnings ratio of 5.01. meaning, the purchaser of the share is investing €5.01 for every euro of annual earnings.

yearly top and bottom value

crcam sud r.a.cci's stock is valued at €115.00 at 01:50 est, way below its 52-week high of €137.80 and higher than its 52-week low of €110.02.

revenue growth

year-on-year quarterly revenue growth declined by 11.1%, now sitting on 381.2m for the twelve trailing months.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 30, 2023, the estimated forward annual dividend rate is 6.22 and the estimated forward annual dividend yield is 5.39%.

more news about crcam sud r.a.cci.

3. barbara bui (bui.pa)

4.08% foward dividend yield

barbara bui's last close was €7.25, 30.95% under its 52-week high of €10.50. intraday change was 0.69%.

barbara bui sa engages in the manufacture, marketing, and sale of ready-to-wear clothing and accessories for women in france and internationally. the company offers coats, jackets, tops and shirts, t-shirts, mesh, pants, dresses and skirts, leather products, and tailored cloths; and accessories, such as shoes, bags, scarves, and belts. it offers its products through wholesale distributors, as well as online and offline stores. the company was incorporated in 1982 and is based in paris, france.

earnings per share

as for profitability, barbara bui has a trailing twelve months eps of €1.04.

pe ratio

barbara bui has a trailing twelve months price to earnings ratio of 6.97. meaning, the purchaser of the share is investing €6.97 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 125.51%.

more news about barbara bui.

4. tipiak (tipi.pa)

2.48% foward dividend yield

tipiak's last close was €86.50, 23.57% above its 52-week high of €70.00. intraday change was 0%.

tipiak société anonyme, a food company, manufactures prepared food products, frozen ready-meals, pastry products, groceries, and crusty bread products. the company offers groceries, such as breadcrumbs, cereals, couscous, croutons, japanese pearls, potato starch, quinoa, and tapioca; frozen products, including savory products, appetizers, and side dishes with grains; and frozen sweet products comprising macarons, mini eclairs, and petits fours. it sells its products in france, england, and the united states. the company was founded in 1830 and is based in saint-aignan-grandlieu, france.

earnings per share

as for profitability, tipiak has a trailing twelve months eps of €1.85.

pe ratio

tipiak has a trailing twelve months price to earnings ratio of 46.76. meaning, the purchaser of the share is investing €46.76 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.88%.

volume

today's last reported volume for tipiak is 257 which is 125.43% above its average volume of 114.

more news about tipiak.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com